1. Introduction {#sec1}
===============

Cystic fibrosis (CF) is associated with gastrointestinal dysmotility such as gastroparesis (GP), gastroesophageal reflux, meconium ileus, distal intestinal obstruction syndrome, and chronic constipation \[[@B1]\]. It is well known that small bowel and total transit time are prolonged in CF \[[@B1]--[@B4]\]. However, the effects of cystic fibrosis on gastric emptying (GE) and the incidence of GP in this population are variable. Studies report either more rapid GE in CF patients compared to controls, slower GE in CF patients, or no difference between both groups.

The diagnosis of GP has serious implications in CF care as it can worsen the chronic malnutrition associated with the disease due to reduced oral caloric intake and reduce patients\' quality of life. GP may also interfere with oral medication delivery and absorption as suggested by studies evaluating pancreatic enzyme replacement therapy (PERT) used in patients with CF and pancreatic insufficiency \[[@B5]\]. About 90% of patients with CF have exocrine pancreatic insufficiency and require regular PERT to improve the digestion of dietary fat, protein, and other nutrients \[[@B6]\]. PERT improves but does not necessarily normalize fat digestion \[[@B5], [@B7], [@B8]\]. Differences in response to PERT may be related to gastric emptying rates, as digestion of fat in patients with CF and pancreatic insufficiency is strongly affected by how rapidly fat enters the duodenum \[[@B9]\]. Additionally, macrolides (e.g., azithromycin) are used as a chronic anti-inflammatory therapy in the patients who suffer from*Pseudomonas* infection in their lungs. This therapy has prokinetic effects that may improve GP or cause GI distress due to rapid gastric emptying \[[@B10], [@B11]\].

This systematic review aims to determine whether patients with CF have slower or faster GE compared to healthy controls. The analysis did not intend to assess whether disorders in gastric emptying were associated with upper gastrointestinal symptoms since symptoms are poor predictors of motility, regardless of the technique used \[[@B12]\].

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

We performed a literature search in September 2014 using PUBMED, EMBASE, Web of Science, and Scopus databases. Two authors (Juan E. Corral and Corey W. Dye), conducted the initial screening independently, using the following search terms: (gastroparesis (MeSH term), gastric emptying (MeSH), or gastric scintigraphy (not MeSH term)) and (cystic fibrosis (MeSH)). No language filters were used. We also reviewed the available abstracts in summaries from major gastroenterology meetings (DDW: Digestive Disease Week, ACG: American College of Gastroenterology, and EUG: United European Gastroenterology), and cystic fibrosis conferences (NACFC: North American Cystic Fibrosis Conference and ECFS: European Cystic Fibrosis Society). We then reviewed the reference lists from retrieved articles to identify further relevant studies. Authors were contacted to provide additional information when an e-mail was provided. This systematic review was planned, conducted, and reported in adherence to MOOSE Group recommendations \[[@B13]\].

2.2. Eligibility Criteria {#sec2.2}
-------------------------

Studies were considered in this systematic review if they met the following inclusion criteria: they were performed in human subjects, included an abstract with a methods section, and provided at least one measurement of gastric emptying using either Tc-Scintigraphy, a wireless capsule, or C-Octanoic breath test. Single case reports and review articles were excluded from our sample but all other available studies (case-series, case controls, cohorts, and clinical trials) were considered for initial analysis. A second selection was done within that group to only include studies that compared CF patients with healthy controls. When multiple publications were reported from the same population, the report with the largest sample was selected. Studies that used nonconventional techniques (e.g., ultrasound and fluoroscopy) or that assessed total intestinal time, small bowel, or colon motility but did not have separate measurements of the stomach motility parameters were excluded from analysis. Studies that measured gastric contractions (e.g., electrogastrography) as an indirect measure of gastric emptying were also excluded. Inclusion was not otherwise restricted by language, study size, or setting.

2.3. Data Extraction {#sec2.3}
--------------------

The following data were extracted from each study: first author\'s last name, publication year, country where the study was performed, study period, sample size (number of patients with CF and controls), participant\'s sex and age, diagnostic modality (e.g., scintigraphy and C-Octanoic scan), type of test meal used to deliver marker (solid meal or liquid), available gastric emptying measurements, and number of cases with diabetes mellitus (DM) and with pancreatic insufficiency. We recorded the following GE measurements: total gastric emptying time, gastric emptying half time (*T* ~1/2~), and percentage of retention at 1, 2, 3, or 4 hours (RR1, RR2, RR3, and RR4). The number of participants with GP according to original manuscript criteria was also documented.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All studies where the percentage of patients with CF and GP could be estimated were included in the initial review. The percentage of patients with GP and corresponding 95% confidence intervals (95% CIs) were calculated using the Poisson distribution. Forest plot graphs were elaborated using a random effects model selected*a priori*.

Primary analysis pooled all studies that included a control comparison group in a similar fashion. Two studies reported gastric emptying means in case and control groups without their respective dispersion measurements (standard deviation). For those cases, we used standard deviations described in other measurements. For example, when mean and standard deviation was provided for RR1 but not for RR2, we used the standard deviation reported for RR1. Studies that did not report point estimates (mean or median) were not included in the systematic review \[[@B14], [@B15]\].

For case control studies, methodological quality was assessed by two authors (Juan E. Corral and Baharak Moshiree) using the 9-star Newcastle-Ottawa Scale \[[@B16]\]. Percentage of agreement and bias index were estimated to measure interobserver agreement.

Subgroup analysis was conducted to evaluate for two effect modifying variables: diagnostic modality and age (mean age less or more than 18 years). Statistical heterogeneity between studies was evaluated by calculating *I* ^2^ statistics. Publication bias was evaluated by visual inspection of funnel plots and Egger\'s bias test. All statistical analyses were performed with Stata version SE 11.2 (Stata-Corp, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

The detailed steps of our literature search are shown in [Figure 1](#fig1){ref-type="fig"}. We identified 43 potentially relevant articles concerning gastric emptying in CF. Fifteen articles were excluded because of duplicate reports from the same study population. Two more studies were excluded because they used electrogastrography reporting contractile activity rather than gastric emptying. Nineteen studies were included in the final review, 9 case control studies, and 10 more without a control group.

3.2. Study Characteristics {#sec3.2}
--------------------------

Nineteen studies were published between 1995 and 2013 and included a total of 574 subjects from 9 different countries (359 patients with CF and 215 controls). See [Table 1](#tab1){ref-type="table"}. Mean age of participants ranged from a few months to 28 years.

Eleven studies used Technetium scintigraphy \[[@B4], [@B17]--[@B24]\], 6 used C-Octanoic breath test \[[@B5], [@B9], [@B25]--[@B27]\], and 2 used wireless motility capsule \[[@B29], [@B30]\]. The test meal used to deliver marker varied between studies. Two studies used liquids, 14 studies used solid food, and two studies used both.

3.3. Frequency of Gastroparesis in Cystic Fibrosis {#sec3.3}
--------------------------------------------------

From all available studies (*n* = 19), we were able to estimate the percentage of patients with GP in 11 studies (4 studies with a control group and 7 studies without control group). Pooled analysis estimated that 37.9% (95% CI 30.4--45.4%) have GP ([Figure 2](#fig2){ref-type="fig"}). Results were highly dependent on the diagnostic modality used. Scintigraphy revealed higher frequency of GP in CF than C-Octanoic test.

Frequency of GP increased with age, 26.6% (95% CI 13.2--39.9%) in studies with patients younger than 18 years compared to 36.3% (20.9--51.7%) seen in older patients (\>18 years), although this difference was not statistically significant.

3.4. Cystic Fibrosis Patients Compared to Healthy Controls {#sec3.4}
----------------------------------------------------------

Overall, 2 studies reported slower GE, 3 reported faster GE, and 4 reported no difference in patients with CF compared to healthy controls. See [Table 2](#tab2){ref-type="table"}. 359 CF patients and 215 controls were included in primary analysis. In the CF group, 51.8% patients were male, 3.1% had DM, and 100.0% had documented exocrine pancreatic insufficiency. In the control group, 55.8% were male, 0% had DM and 4.38% pancreatic insufficiency.

Four Tc-Scintigraphy studies reported RR1 and RR2, 2 wireless motility capsule studies reported RR3, and 3 studies reported *T* ~1/2~ using different techniques. No studies reported RR4 which is now the standardized protocol recommended by the National Nuclear Medicine Society and the Neurogastroenterology and Motility Society \[[@B31]\].

Pooled comparison of the 4 scintigraphy studies \[[@B4], [@B14], [@B15], [@B23]\] reporting retention rates (RR) in 1 or 2 hours favored faster gastric emptying in CF (RR1 SMD −1.62 (95% CI −2.16 −1.09) and RR2 SMD −0.96 (95% CI −1.44 −0.47)). No pooled analysis could be performed for wireless motility studies or C-Octanoic tests, due to missing information.

Within the scintigraphy group, 3 studies showed faster gastric emptying and 2 slower gastric emptying in CF patients. See [Table 2](#tab2){ref-type="table"}. One study reported no difference between groups and the remaining studies did not have any comparison group. Of note, Kuo et al. proved that gastric emptying is faster in CF but adequate PERT slowed gastric emptying substantially to a rate comparable to healthy subjects.

Patients with CF in the studies that revealed rapid gastric emptying were younger than patients in other studies using scintigraphy. Sample size was also smaller (16, 36, 11 versus 88, 101) in those studies. See [Table 1](#tab1){ref-type="table"}.

3.5. Risk of Bias Assessment {#sec3.5}
----------------------------

All studies had small samples (range 10--101), and most had methodological or reporting limitations. Mean Newcastle-Ottawa score was 4.5 (range 1--9). Interobserver agreement between the two reviewers was 35.7% and bias index was 0.36. Heterogeneity was significant (*I* ^2^ range 89--94%). A funnel plot was elaborated for studies included in primary analysis and Egger\'s bias coefficient was 3.58 (95% CI 2.01--5.16).

4. Discussion {#sec4}
=============

This systematic review shows that patients with CF have a high frequency of GP, up to 38% (95% CI 30--45%) according to our estimates. The prevalence of GP in general population is probably low (age-adjusted incidence estimated to be 2.4 per 100,000 person-years for men and 9.8 per 100,000 person-years for women) \[[@B32]--[@B34]\]. Our estimate in CF is elevated but still less than the prevalence seen in high-risk groups like diabetics with upper gastrointestinal symptoms, of which 50--65% are diagnosed with GP \[[@B35]--[@B37]\]. We also found a higher prevalence of GP in CF studies with patient populations older than 18 years.

Gastroparesis is a diverse syndrome that varies by gender, body mass, symptoms, and severity of gastric emptying delay \[[@B38]\]. The mechanisms through which patients with CF develop GP are likely multifactorial and coexist with a subgroup of patients with rapid gastric emptying.

CF is associated with dysmotility disorders including gastroesophageal reflux, distal intestinal obstruction syndrome, and chronic constipation. Studies using knock-out mice show that the decreased intestinal motility is not caused directly by loss of CFTR but rather that it is a consequence of sequential events associated with small intestinal bacterial overgrowth, luminal viscosity, and inflammation \[[@B39], [@B40]\]. It is unlikely that the above mechanisms cause GP as these derangements develop downstream in the gastrointestinal tract. However, we hypothesize that multiple neurologic reflexes and neurohumoral pathways induce GP in CF like in other patients with chronic constipation. These reflexes include an abnormal persistence of normal feedback mechanisms from the small bowel (prolonged ileal inhibition of gastric emptying), colonic stasis affecting gastric emptying via neural reflexes, and an abnormal circulating gastrointestinal hormone response to standard oral stimulus \[[@B41]\].

In addition to constipation, malnutrition and a lower BMI have been found to predict delayed gastric emptying in the general population and in patients with CF \[[@B20]\]. The exact mechanism is not clear but critical illness generally induces a high inflammatory state that has been associated with severe GP \[[@B42]\]. Chronic use of opiates and anticholinergics, frequently used in CF, can also decrease gastric emptying and intestinal transit time. Finally, DM is the main cause of secondary GP in adults. Diabetes did not seem to be relevant in this systematic review as it was documented in only 3% of our sample. It is important to consider that only one study reported glucose intolerance or postprandial hyperglycemia. These two disorders can significantly alter GES and would have been missed by strict DM criteria \[[@B43]\].

Despite the high prevalence of GP, no significant difference was found when comparing RR1 and RR2 between CF patients and controls. We attribute this to the broad spectrum of study populations and the different test meals used to diagnose GP. Up to now, scintigraphy is recognized as the gold standard method for studying GE \[[@B44]\]. Three scintigraphy reports described GE to be faster in CF than in controls. Patients enrolled in these studies were younger than patients in the other scintigraphy studies (mean age 12.6--25.8 versus 16.7--28). Risk of bias in both groups of studies was similar (5.5, 7, 5 versus 4, 4.5) but the first group had smaller samples (63 versus 189). Of note, Kuo et al. showed that, without PERT, patients with CF have faster gastric emptying after a high-fat/high-carbohydrate meal, compared with healthy subjects. The authors hypothesized that reduced fat digestion causes diminished small intestinal feedback \[[@B23]\].

Scintigraphy results are highly dependent on the technique used (i.e., type of meal and caloric contents, follow-up time, and degree of hyper or hypoglycemia). To address this issue, the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine recommended standardized testing in 2008 \[[@B31]\]. Of all scintigraphy studies, only 5 conducted after the consensus recommendations were published and none of them were compliant with the recommendations. Our work emphasizes the need to adopt this standardized protocol to increase reliability and credibility of future research \[[@B31]\].

Results from studies using techniques other than scintigraphy should be interpreted with caution. C-Octanoic breath tests require a normal small bowel absorption and pulmonary function. While intestinal absorption can be almost normal with PERT, pulmonary deterioration is the hallmark of CF. Of all the new techniques, capsule devices have shown promising results. A study reported that wireless motility capsule (Smartpill^©^) had a 38% discordance with conventional testing and provided new dysmotility diagnoses in 53% of patients \[[@B12]\]. Both studies using capsule methodologies revealed no difference between CF patients and controls.

Regarding the methods to deliver markers, the classification of solid or liquid is oversimplistic. When a mixed (liquid plus solid) meal is used, GE rate correlates with liquid emptying better than solid emptying \[[@B45]\]. Differential emptying of solids and liquids occur and alterations in the former do not predict alterations in the latter \[[@B46]\]. Only one study using a solid and liquid test meal reported similar GE rates for both solids and liquids \[[@B47]\]. Again, we advocate for standardized testing whether by scintigraphy or wireless motility testing \[[@B31]\].

In this systematic review the risk for selection bias is significant and particularly for the primary analysis. Given the scarcity of complete readings on GE, only 9 out of the 19 studies were considered acceptable quality and included controls. One study included only patients postlung transplant leading to possible overestimation of GP incidence \[[@B48]\]. Transplant recipients are at increased risk of GI disturbances related to vagal nerve damage after surgery. These patients are known to have GP and are at high risk of developing gastric bezoars \[[@B49]\].

We found significant heterogeneity in GE for the reasons mentioned above and also for the time intervals used. Retention rates at 4 hours are significantly more accurate than 1 or 2 hours readings and studies that provided 4-hour measurements after contrast ingestion were limited \[[@B50]\]. Half emptying times (*T* ~1/2~) have even less sensitivity compared to RR1 and RR2. In addition to technical limitations on measurements, the majority of studies had low scores in study design and reporting according to the Newcastle-Ottawa score. Publication bias is possible with the funnel plot suggesting paucity of small studies (large standard error) showing a low incidence of GP.

Although subgroup analysis was performed, only two variables could be included in our model (age and diagnostic modality). Our sample size was too small to allow for metaregression and evaluate for other effect modifying variables. Furthermore, we could not assess the effect of medications on gastric emptying. Future studies that explore the effects of other medications other than PERT (in particular opioids, macrolides, and laxatives like polyethylenglycol) and glucose intolerance in addition to DM are suggested.

This study has significant strengths. This is the first systematic review to assess gastric emptying in CF. We have shown a higher frequency of GP in CF and described the general characteristics of CF patients with rapid gastric emptying as essentially younger patients, with pancreatic insufficiency and PERT held while being tested. We advocate use of standardized testing in this population to evaluate gastric emptying. Delayed emptying is likely a multifactorial process, driven by abnormal neurologic reflexes and neurohumoral pathways, and diabetes is unlikely to play a significant role. There is significant heterogeneity with paucity of high quality studies and possibly interrater disagreement even though bias index was mild-moderate \[[@B51]\].

5. Conclusion {#sec5}
=============

Patients with CF have a high frequency of GP. No significant difference was found when comparing patient with CF to healthy controls by using RR1 or RR2, likely secondary to differences in study design, sample selection, and diagnostic technique used. There is a clearly identified group of patients with CF that have rapid gastric emptying seen with scintigraphy, in small studies enrolling young patients with pancreatic insufficiency not taking PERT before testing.
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###### 

Studies evaluating gastric emptying in cystic fibrosis.

  Author                          Year   Location           Subjects   Gender   Age       DM                Pancreatic insufficiency   Intervention   Result                                                                                                                  
  ------------------------------- ------ ------------------ ---------- -------- --------- ----------------- -------------------------- -------------- -------- -------------- -------------- ----------------- -------------- ----------------------------------------------- ------------------
   Capsule methods                                                                                                                                                                                                                                                            
  Hedsund et al. \[[@B29]\]       2012   Denmark            10         16       **26**    5                 9                          23             26       0              0              10                0              No                                              No difference
  Gelfond et al. \[[@B30]\]       2013   Buffalo, NY        10         10       **20**    3                 3                          21.7           22.5     0              0              10                0              No                                              No difference
                                                                                                                                                                                                                                                                              
   C-Octanoic breath test                                                                                                                                                                                                                                                     
  De Boeck et al. \[[@B5]\]       1998   Belgium            11         ---      **11**    4                 ---                        10.5           ---      ---            ---            11                ---            Creon and high-lipase Creon in CF.              No control group
  Symonds et al. \[[@B9]\]        2003   Australia          10         12       **22**    5                 7                          10.2           12.5     NA             0              10                0              Pancreas in CF                                  No difference
  Neumann et al. \[[@B25]\]       2003   Czech Republic     20         ---      **20**    NA                ---                        13.5           ---      ---            ---            ---               ---            No                                              No difference
  Hauser et al. \[[@B26]\]        2010   Belgium            19         ---      **19**    13                ---                        5              ---      ---            ---            ---               ---            No                                              No control group
  Pauwels et al. \[[@B28]\]       2011   Belgium            33         ---      **33**    18                ---                        28             ---      0              ---            31                ---            No                                              No control group
  Hauser et al. \[[@B27]\]        2013   Belgium            22         ---      **22**    12                ---                        9              ---      ---            ---            0                 ---            No                                              No control group
                                                                                                                                                                                                                                                                              
   Scintigraphy with technetium                                                                                                                                                                                                                                               
  Davidson et al. \[[@B17]\]      1995   Canada             70         ---      **70**    NA                ---                        NA             ---      ---            ---            ---               ---            No                                              No control group
  Carney et al. \[[@B14]\]        1995   Australia          5          11       **16**    3                 4                          25             21       0              0              5                 0              No                                              CF Faster
  Collins et al. \[[@B15]\]       1997   Australia          19         17       **36**    8                 8                          12.6           12.8     2              0              19                0              Usual dose of PERT in CF                        CF Faster
  Munck et al. \[[@B18]\]         1997   France             7          ---      **7**     NA                ---                        NA             ---      ---            ---            ---               ---            Erythromycin in CF                              No control group
  Couturier et al. \[[@B19]\]     2004   France             48         53       **101**   NA                42                         NA             31.84    NA             0              NA                0              No                                              CF Slower
  King et al. \[[@B20]\]          2006   Australia          22         ---      **22**    8                 ---                        NA             ---      ---            ---            18                ---            Usual dose of PERT in CF                        No control group
  Tonelli et al. \[[@B21]\]       2009   Gainesville, FL    5          ---      **5**     1                 ---                        25.2           ---      2              ---            5                 ---            IV Erythromycin in CF                           No control group
  Luu et al. \[[@B22]\]           2011   Canada             17         ---      **17**    NA                ---                        NA             ---      ---            ---            ---               ---            Measurements before and after Cisapride in CF   No control group
  Kuo et al. \[[@B23]\]           2011   Australia          5          6        **11**    3                 3                          25.8           21.7     0              0              5                 6              Creon versus Placebo in CF                      CF Faster
  Mendez et al. \[[@B24]\]        2012   Chicago, Il        10         78       **88**    8                 38                         28             59       NA             NA             NA                NA             No                                              CF Slower
  Rovner et al. \[[@B4]\]         2013   Philadelphia, PA   16         12       **28**    9                 6                          16.7           28.6     0              0              16                0              Creon in CF                                     No difference
                                                            359        215      **574**   100 (50.76%)^a^   120 (55.81%)^a^                                    4 (5.71%)^a^   0 (0.00%)^a^   140 (84.85%)^a^   6 (4.38%)^a^                                                    

^a^Of available data.

CF: cystic fibrosis and NA: data not available.

###### 

Case-control (higher-quality) studies evaluating gastric emptying in cystic fibrosis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                         Sample *n* = 348  (CF/control)   Cystic fibrosis                                                     Controls matching            Food used to deliver marker   PERT before testing                                                                             Follow-up time                            NOS\                                                     Conclusion                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                           Rater 1/Rater 2                                                                                                                                                                                                           
  ------------------------------ -------------------------------- ------------------------------------------------------------------- ---------------------------- ----------------------------- ----------------------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------- --------------------------------------------- ---------------------------------------- -------- --------------------------------- ------------------------ ----- --------------------------------------------------------------------------------------------------------------------
  Capsule methods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Hedsund et al. \[[@B29]\]      26 (10/16)                       All had severe classes I--III mutations (7 were ΔF508 homozygote)   0 (0%)                       22                            All cases (confirmed by fecal elastase)                                                         NA                                        GI medication, antibiotics, and probiotics held \>72 h   Unmatched                                     MTS-1 Capsule fasting                    NA       Held                              7 h max                  3/6   No difference (CF slower, but *p* \> 0.05)

  Gelfond et al. \[[@B30]\]      20 (10/10)                       Sweat Cl \> 60 mmol/L or 2\                                         0 (0%)                       22.9                          All cases (confirmed by fecal elastase, coefficient of fat absorption or serum trypsinogen)     FEV1 \> 25% predicted                     Antiacids and antibiotics held \>1 week                  Age, sex, BMI                                 Smartpill with low fat meal bar          Solid    Half their usual dose             72 h max                 5/6   No difference
                                                                  CF mutations (6 were ΔF508 homozygote)                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  C-Octanoic breath test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Symonds et al. \[[@B9]\]       22 (10/12)                       Sweat Cl \> 80 mmol/L or "genotype determination"                   NA                           NA                            All cases (confirmed by coefficient of fat absorption or steatorrhea + microscopic stool fat)   NA                                        Not taking any GI motility medication                    Unmatched                                     Pancake, toast, orange juice, and milk   Solid    Usual dose                        8 h                      3/6   No difference

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Scintigraphy with technetium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Carney et al. \[[@B14]\]       16 (5/11)                        NA                                                                  0 (0%)                       NA                            All cases (confirmed by steatorrhea + high 3-day fecal fat)                                     FEV1 \> 50% predicted                     NA                                                       Unmatched                                     Soup and olive oil                       Liquid   Held 14 h prior                   2 h                      4/7   GE of fat is faster in CF

  Collins et al. \[[@B15]\]      36 (19/17)                       NA                                                                  2 (10.5%)                    NA                            All cases (confirmed by high 3-day fecal fat)                                                   NA                                        Not taking any GI motility medication \>4 days           Age, sex                                      Pancake                                  Solid    Usual dose                        2 h                      7/7   GE is faster in CF

  Couturier et al. \[[@B19]\]    101 (48/53)                      NA                                                                  NA                           NA                            NA                                                                                              Severe pulmonary disease pre transplant   NA                                                       Unmatched                                     Egg, bread meal, and water               Solid    NA                                2/3 of stomach emptied   5/4   GE is slower in CF (*p* = 0.001)

  Kuo et al. \[[@B23]\]          11 (5/6)                         NA                                                                  0 (0%)\                      20.0                          All cases (NA)                                                                                  NA                                        NA                                                       Unmatched                                     Smashed potatoes                         Solid    Crossover\                        3 h                      4/6   GE is faster in CF (*p* \< 0.001). But PERT slowed GE substantially in CF to a rate comparable to healthy subjects
                                                                                                                                      1 with glucose intolerance                                                                                                                                                                                                                                                                                                                                    Arm 1: no enzymes.\                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Arm 2: twice the usual dose                                      

  Mendez et al. \[[@B24]\]       88 (10/78)                       NA                                                                  NA                           20                            NA                                                                                              Postlung transplant                       NA                                                       Both CF and controls had lung transplant^a^   Egg                                      Solid    NA                                1.5 h                    4/4   Both groups had delayed GE, but CF \> controls (44% and 29%, resp.)

  Rovner et al. \[[@B4]\]        28 (16/12)                       NA                                                                  0 (0%)                       19.6                          All cases (confirmed by a fecal elastase)^b^                                                    FEV1 \> 50% predicted                     NA                                                       Unmatched                                     Chocolate shake                          Liquid   Standard dose (80,000 lipase U)   6 h                      6/9   No difference
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^78 controls had end-stage pulmonary disease: 36, COPD; 32, idiopathic pulmonary fibrosis; 7, alpha-1-antitrypsin deficiency; and 3, scleroderma.

^b^Four subjects with CF had history of distal DIOS and 1 had history of bacterial overgrowth not being treated at the time of study.

GE = gastric emptying.

CF: cystic fibrosis, NOS: Newcastle-Ottawa score, NA: data not available, DM: diabetes mellitus, and DIOS: distal intestinal obstructive syndrome.
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